Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MOLN
Stock Latest News
Company Announcements
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
6d ago
6K
MOLN
Premium
The Fly
Molecular Partners doses first patients in MP0317 combination study
10d ago
MOLN
Premium
Company Announcements
Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging
19d ago
6K
MOLN
Premium
Ratings
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
24d ago
MOLN
Premium
Company Announcements
Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial
24d ago
6K
MOLN
Premium
The Fly
Molecular Partners, Orano Med doses first patient in MP0712 study
24d ago
MOLN
Premium
Company Announcements
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
2M ago
6K
MOLN
Premium
The Fly
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
2M ago
MOLN
Premium
Ratings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
2M ago
MOLN
Premium
Company Announcements
Molecular Partners Advances Radio-DARPin and Immuno-Oncology Pipeline on Solid Financial Footing in Q1 2026
2M ago
6K
MOLN
Premium
Company Announcements
Molecular Partners Showcases Nature Cancer Phase 1 Data and Advances MP0317 Into Phase 2 Cholangiocarcinoma Trial
3M ago
6K
MOLN
Premium
The Fly
Molecular Partners publishes MP0317 clinical data in Nature Cancer
3M ago
MOLN
Premium
Ratings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
3M ago
MOLN
Premium
The Fly
Molecular Partners announces presentation of preclinical data at AACR
3M ago
MOLN
Premium
Company Announcements
Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
3M ago
6K
MOLN
Premium
Company Announcements
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
4M ago
6K
MOLN
Premium
Market News
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
4M ago
MOLN
SVCO
Premium
Ratings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
4M ago
MOLN
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
4M ago
MOLN
Premium
Company Announcements
Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
4M ago
6K
MOLN
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
4M ago
MOLN
Premium
Company Announcements
Molecular Partners Publishes 2025 Report as Radio-DARPin Pipeline Enters Key Clinical Phase
5M ago
6K
MOLN
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
